<ul><li>2.3 million newborns die of severe bacterial infections each year, the experts said in a report published in the December 2022 Bulletin of the <keyword id="43588" type="General" weightage="50" keywordseo="world-health-organization" source="Orion">World Health Organization</keyword>.</li><li>Over the last decade, <keyword id="149212" type="General" weightage="80" keywordseo="amr" source="Orion">AMR</keyword> has worsened to the point where around 50-70 per cent of common pathogens show a high degree of resistance to available first and second-line antibiotics, they said.</li><li>According to the report, ethical concerns, logistical issues and regulatory requirements have made it difficult to conduct clinical research in newborns.</li></ul>There is an urgent need to develop antibiotics for newborn babies, a population that is particularly vulnerable to antibiotic resistance, according to leading global public health experts including those from India. Recent estimates show about 2.3 million newborns die of severe bacterial infections each year while an increasing number are becoming resistant to currently used antibiotics, the experts said in a report published in the December 2022 Bulletin of the World Health Organization. Over the last decade, AMR has worsened to the point where around 50-70 per cent of common pathogens show a high degree of resistance to available first and second-line antibiotics, they said. The paper is co-authored by international experts in the field of antimicrobial resistance (AMR), including those from the Global Antibiotic Research &amp; Development Partnership (GARDP) and <keyword id="6365231" type="General" weightage="50" keywordseo="all-india-institute-of-medical-sciences" source="Orion">All India Institute of Medical Sciences</keyword> (<keyword id="40458" type="General" weightage="50" keywordseo="aiims" source="Orion">AIIMS</keyword>). The authors noted that despite substantial progress in medical research and a steep decline in the number of children under the age of five who die of preventable diseases, many problems related to child health remain to be tackled. Severe bacterial infections are one of them. "There is an urgent need to identify high priority antibiotics to understand which ones work best and safely in children, and then make them available where they are needed," said <keyword id="15914044" type="General" weightage="50" keywordseo="mike-sharland" source="Orion">Mike Sharland</keyword> from St George's, <keyword id="125994" type="General" weightage="50" keywordseo="university-of-london" source="Orion">University of London</keyword> (SGUL), and member of the <keyword id="15914043" type="General" weightage="50" keywordseo="antimicrobial-resistance-programme" source="Orion">Antimicrobial Resistance Programme</keyword> at Penta - Child Health Research. "By achieving global consensus, we can streamline the process of antibiotic development, allow for faster access to antibiotics, and reduce the burden of AMR on the vulnerable neonatal population," added <keyword id="1651099" type="General" weightage="50" keywordseo="manica-balasegaram" source="Orion">Manica Balasegaram</keyword>, Executive Director of GARDP. The report also highlights how collaborative antibiotic development and access network specifically targeting newborns could also prove valuable compared to single independent studies. A successful example, the authors noted, has been the collaboration between GARDP, Penta - Child Health Research, SGUL, and other partners on a recent global observational study of 3,200 babies with neonatal sepsis across 19 hospitals in 11 countries. They are also partnering on an upcoming clinical trial, which will start in South Africa within the next few months before being expanded to other countries. Despite a rising number of newborn deaths caused by AMR, very few effective antibiotics have been adequately studied to treat serious bacterial infections such as neonatal sepsis, the authors said. As many as 40 antibiotics approved for use in adults since 2000, only four have included dosing information for newborns in their labels, they said. According to the report, ethical concerns, logistical issues and regulatory requirements have made it difficult to conduct clinical research in newborns. There is a long delay in completing paediatric regulatory studies and they are also not harmonised globally to demonstrate clinical utility in newborns, it said. SEE ALSO: <a href="https://www.businessinsider.in/tech/news/ces-2023-dates-news-products-and-what-to-expect/articleshow/96591686.cms">All-new Apple CarPlay features to AI for automobiles — here are some car technologies expected to arrive in 2023</a> <a href="https://www.businessinsider.in/tech/news/ces-2023-dates-news-products-and-what-to-expect/articleshow/96591686.cms">CES 2023: Dates, news, products, and what to expect</a>

Urgent need to develop antibiotics for newborns say global experts

There is an urgent need to develop antibiotics for newborn babies, a population that is particularly vulnerable to antibiotic resistance, according to leading global public health experts including those from India. Recent estimates show about 2.3 million newborns die of severe bacterial infections each year while an increasing number are becoming resistant to currently used antibiotics, the experts said in a report published in the December 2022 Bulletin of the <keyword id="43588" type="General" weightage="50" keywordseo="world-health-organization" source="Orion">World Health Organization</keyword>. Over the last decade, <keyword id="149212" type="General" weightage="80" keywordseo="amr" source="Orion">AMR</keyword> has worsened to the point where around 50-70 per cent of common pathogens show a high degree of resistance to available first and second-line antibiotics, they said. The paper is co-authored by international experts in the field of antimicrobial resistance (AMR), including those from the Global Antibiotic Research &amp; Development Partnership (GARDP) and the <keyword id="6365231" type="General" weightage="50" keywordseo="all-india-institute-of-medical-sciences" source="Orion">All India Institute of Medical Sciences</keyword> (<keyword id="40458" type="General" weightage="50" keywordseo="aiims" source="Orion">AIIMS</keyword>). The authors noted that despite substantial progress in medical research and a steep decline in the number of children under the age of five who die of preventable diseases, many problems related to child health remain to be tackled. Severe bacterial infections are one of them. "There is an urgent need to identify high-priority antibiotics to understand which ones work best and safely in children, and then make them available where they are needed," said <keyword id="15914044" type="General" weightage="50" keywordseo="mike-sharland" source="Orion">Mike Sharland</keyword> from St George's, <keyword id="125994" type="General" weightage="50" keywordseo="university-of-london" source="Orion">University of London</keyword> (SGUL), and member of the <keyword id="15914043" type="General" weightage="50" keywordseo="antimicrobial-resistance-programme" source="Orion">Antimicrobial Resistance Programme</keyword> at Penta - Child Health Research. "By achieving global consensus, we can streamline the process of antibiotic development, allow for faster access to antibiotics, and reduce the burden of AMR on the vulnerable neonatal population," added <keyword id="1651099" type="General" weightage="50" keywordseo="manica-balasegaram" source="Orion">Manica Balasegaram</keyword>, Executive Director of GARDP. The report also highlights how collaborative antibiotic development and access networks specifically targeting newborns could also prove valuable compared to single independent studies. A successful example, the authors noted, has been the collaboration between GARDP, Penta - Child Health Research, SGUL, and other partners on a recent global observational study of 3,200 babies with neonatal sepsis across 19 hospitals in 11 countries. They are also partnering on an upcoming clinical trial, which will start in South Africa within the next few months before being expanded to other countries. The authors said that despite a rising number of newborn deaths caused by AMR, very few effective antibiotics have been adequately studied to treat serious bacterial infections such as neonatal sepsis. As many as 40 antibiotics have been approved for use in adults since 2000, but only four have included dosing information for newborns in their labels, they said. According to the report, ethical concerns, logistical issues and regulatory requirements have made it difficult to conduct clinical research on newborns. There is a long delay in completing paediatric regulatory studies and they are also not harmonised globally to demonstrate clinical utility in newborns, it said. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/business/corporates/news/indias-agrochemicals-industry-to-see-double-digit-growth-in-fy23-and-fy24-on-strong-exports-boost-says-crisil/articleshow/96572842.cms">India’s agrochemicals industry to see double-digit growth in FY23 and FY24 on strong exports boost, says Crisil</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/science/health/news/from-egypt-to-belarus-countries-that-are-covid-free-amid-a-global-rise-in-cases/slidelist/96591191.cms">From Egypt to Belarus: Countries that are Covid free amid a global rise in cases</a>

In a move towards advancing research and innovation in the pharmaceutical and medical technology (<keyword id="20251757" type="General" weightage="100" keywordseo="pharma-medtech" source="Orion">Pharma-MedTech</keyword>) sector, the Ministry of Finance announced the "Promotion of Research and Innovation in Pharma-MedTech" (#PRIP) initiative. The Ministry of Finance posted on X, "Promotion of Research and Innovation in Pharma-MedTech #PRIP was announced as a long-term scheme to help strengthen pharmaceutical #infrastructure and boost research in six moon-shot areas. #PromisesDelivered" https://twitter.com/finminindia/status/1748186041646031329?s=48&amp;t=CSE0glwGSDCXRHUtG7cLjw This long-term scheme aims to fortify pharmaceutical infrastructure and propel research across six transformative areas. The announcement, made through the ministry's official handle on X, showcased the government's commitment to fostering advancements in the healthcare industry. Under the banner of the Department of Pharmaceuticals, the <keyword id="5614387" type="General" weightage="20" keywordseo="prip" source="Orion">PRIP</keyword> initiative has made substantial progress since its inception in the fiscal year 2023-24. The scheme, with a budgetary allocation of Rs 5,000 crore, received approval from the Cabinet and was officially notified on August 17, 2023. The first component focuses on enhancing research infrastructure through the establishment of seven Centres of Excellence (CoEs) at National Institute of Pharmaceutical Education and Research (NIPER) institutes. These CoEs, strategically located in pre-identified areas, are allocated a financial outlay of Rs 700 crore. The second component of PRIP is dedicated to promoting research in the pharmaceutical sector across six moon-shot areas. The areas of focus include new chemical entities, complex generics (including biosimilars), medical devices, stem cell therapy, orphan drugs, and anti-microbial resistance. A financial assistance of Rs 4,250 crore will be extended to companies collaborating with government institutes and conducting in-house research and development (R&amp;D) in these priority areas. The Ministry of Finance envisions the PRIP scheme as a transformative programme designed to elevate the research and innovation landscape in the pharma-medtech sector. By establishing Centres of Excellence and providing financial support for groundbreaking research, the government aims to bolster India's position in pharmaceutical advancements globally. As part of the PRIP initiative, the government will actively encourage industry players to invest in research and development, focusing on specific priority areas outlined in the scheme. This collaborative approach between the government and private entities is expected to drive innovation, address critical healthcare challenges, and contribute to the overall growth of the pharma-medtech sector in India. The PRIP scheme stands as a testament to the government's commitment to fostering a robust ecosystem for research and innovation, aligning with the broader vision of building a self-reliant and cutting-edge pharmaceutical industry in the country. With a clear focus on transformative areas, PRIP is poised to shape the future trajectory of the pharma-medtech sector in India.

You Searched For "antimicrobial resistance programme" and got 3 results

Urgent need to develop antibiotics for newborns say global experts

PTI

Urgent need to develop antibiotics for newborns say global experts

PTI

Boosting Pharma-MedTech: India allocates Rs 5,000 crore to propel research and innovation

ANI